<img height="1" width="1" src="https://www.facebook.com/tr?id=200201724533423&amp;ev=PageView &amp;noscript=1">
Contact Us

    Genomind To Spend Week Educating Industry Leaders

    Published on Feb 12, 2013 5:50:11 PM

    Activities to Include Interactive Webinar and Exhibition at NPA’s Psychopharmacology Update Conference

    CHALFONT, PA – February 12, 2013 – Genomind, a personalized medicine company, is pleased to embark on a solid week of education and promotion of the Genecept™ Assay. This week, Genomind will be hosting both an informational webinar and exhibiting at the Nevada Psychiatric Association 18th Annual Psychopharmacology Update conference.

    Today, Genomind will host a complimentary educational webinar, “From Treating Illness to Treating Individuals: How Biomarkers Are Advancing Psychiatry,” featuring Dr. Jay Lombard, Chief Scientific Officer and Medical Director. Dr. Lombard will present a session about the importance of biomarkers in psychiatry, and the clinical application of and benefits provided by Genomind’s Genecept Assay — a simple to use, saliva-based test which analyzes a patient’s genetic make-up to help inform clinician treatment decisions for difficult-to-treat patients with psychiatric diagnoses. Dr. Lombard will discuss the proprietary 10-gene panel, and share how clinicians are using this valuable information in their practices today.

    All those interested in learning more are invited to join. The 1-hour webinar will run at both 2:00 PM EST and 8:30 PM EST. Contact info@genomind.com to register and receive an access link to the session.

    From February 13-17, Genomind will be at the Annual Psychopharmacology Update conference in Las Vegas. The Annual Psychopharmacology Update is the largest psychopharmacology conference in the U.S., and in 2013 is even bigger with additional conference days dedicated to geropsychiatry and medical/psychiatric interface.

    For the second year, Genomind will be on the main show floor at Booth 201 to connect with industry experts, share information about the new clinician portal, and educate medical professionals on their dedication to harnessing the latest research to better treat patients.

    Both of these activities will highlight Genomind’s commitment to discovery, product development, and improvement of patient outcomes through education.

    About the Genecept Assay

    The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.

    About Genomind

    Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

    For more information, contact:

    Adam Shapiro

    Amy Pressman
    Marketing Manager, Genomind


    Topics: Uncategorized